CLINICAL ROLE -
Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.
Read More